Mesenchymal stem cell transplantation alleviates experimental Sjogren's syndrome through IFN-β/IL-27 signaling axis.

ABSTRACT: Rationale: Although mesenchymal stem cell (MSC) transplantation has been proved to be an effective therapeutic approach to treat experimental Sjögren's syndrome (SS), the detailed underlying mechanisms remains unknown. IL-27 has diverse influences on the regulation of T cell differentiation and was involved in SS through modulating immune response. Here we aimed to explore whether IL-27-mediated regulation of immune cells was responsible for the beneficial effects of MSC transplantation on SS. Methods: The SS-like symptoms were evaluated in IL-27 deficient and recombinant IL-27-treated NOD mice. The MSCs were infused into NOD mice via the tail vein. The histological features of submandibular glands, saliva flow rate and serum IL-27 were examined. The effects of MSCs on the IL

SUBMITTER: Yao G 

PROVIDER: S-EPMC6857067 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature